Thus, it can be deduced that peripheral CB1R hyperactivation promotes obesity-associated fatty liver, suggesting that the CB1R blockade could serve as a therapeutic strategy for NAFLD. The gene discussed is CNR1; the disease is obesity due to melanocortin 4 receptor deficiency.